Abstract:What's New? Pancreatic adenocarcinoma is characterized by a high stroma content and an immunosuppressive tissue environment. Here, the authors investigated the capacity of vaccinia viruses to stimulate the human innate immune system upon exposure to pancreatic carcinoma cells. Infection of pancreatic adenocarcinoma cells with modified and novel cytokine‐armed vaccinia viruses led to cellular re‐programming of core signaling pathways and initiation of immunogenic cell death that stimulated natural killer cells and resulted in enhanced cytotoxicity. Natural killer cell activation by cytokine‐armed vaccinia viruses shows great potential for immune modulation in the pancreatic duct adenocarcinoma microenvironment. Pancreatic ductal adenocarcinoma (PDAC) remains a particularly aggressive disease with few effective treatments. The PDAC tumor immune microenvironment (TIME) is known to be immune suppressive. Oncolytic viruses can increase tumor immunogenicity via immunogenic cell death (ICD). We focused on tumor‐selective (vvDD) and cytokine‐armed Western‐reserve vaccinia viruses (vvDD‐IL2 and vvDD‐IL15) and infected carcinoma cell lines as well as patient‐derived primary PDAC cells. In co‐culture experiments, we investigated the cytotoxic response and the activation of human natural killer (NK). Infection and virus replication were assessed by measuring virus encoded YFP. We then analyzed intracellular signaling processes and oncolysis via in‐depth proteomic analysis, immunoblotting and TUNEL assay. Following the co‐culture of mock or virus infected carcinoma cell lines with allogenic PBMCs or NK cell lines, CD56+ NK cells were analyzed with respect to their activation, cytotoxicity and effector function. Both, dose‐ and time‐dependent release of danger signals following infection were measured. Viruses effectively entered PDAC cells, emitted YFP signals and resulted in concomitant oncolysis. The proteome showed reprogramming of normally active core signaling pathways in PDAC (e.g., MAPK–ERK signaling). Danger‐associated molecular patterns were released upon infection and stimulated co‐cultured NK cells for enhanced effector cytotoxicity. NK cell subtyping revealed enhanced numbers and activation of a rare CD56dimCD16dim population. Tumor cell killing was primarily triggered via Fas ligands rather than granule release, resulting in marked apoptosis. Overall, the cytokine‐armed vaccinia viruses induced NK cell activation and enhanced cytotoxicity toward human PDAC cells in vitro. We could show that cytokine‐armed virus targets the carcinoma cells and thus has great potential to modulate the TIME in PDAC.

Oncolytic vaccinia virus armed with 4-1BBL elicits potent and safe antitumor immunity and enhances the therapeutic efficiency of PD-1/PD-L1 blockade in a pancreatic cancer model

4-1Bbl-armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma

A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer

Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8+T cell function and its impact against pancreatic ductal adenocarcinoma

AVL-armed oncolytic vaccinia virus promotes viral replication and boosts antitumor immunity via increasing ROS levels in pancreatic cancer

An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy

Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer

An Engineered Oncolytic Vaccinia Virus Encoding a Single-Chain Variable Fragment Against TIGIT Induces Effective Antitumor Immunity and Synergizes with PD-1 or LAG-3 Blockade.

OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment

Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model

Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression

CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model

Radiofrequency Hyperthermia Enhances Locally Delivered Oncolytic Immuno-Virotherapy for Pancreatic Adenocarcinoma

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade

An Oncolytic HSV-1 Armed with Visfatin Enhances Antitumor Effects by Remodeling Tumor Microenvironment Against Murine Pancreatic Cancer

Cytokine‐armed vaccinia virus promotes cytotoxicity toward pancreatic carcinoma cells via activation of human intermediary CD56dimCD16dim natural killer cells

Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy

Enhanced Antitumor Efficacy Of A Novel Oncolytic Vaccinia Virus Encoding A Fully Monoclonal Antibody Against T-Cell Immunoglobulin And Itim Domain (Tigit)

The Oncolytic virus VT1092M and an Anti-PD-L1 antibody synergize to induce systemic antitumor immunity in a murine bilateral tumor model

Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.

Intratumoral Delivery Of A Pd-1-Blocking Scfv Encoded In Oncolytic Hsv-1 Promotes Antitumor Immunity And Synergizes With Tigit Blockade